Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Price:
0.227 USD
-3.81%
Market Closed
Updated:
May 21, 2024
Sonoma Pharmaceuticals Inc
Accounts Receivables
|
Sonoma Pharmaceuticals Inc
Accounts Receivables Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Accounts Receivables
$2.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accounts Receivables
$14.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accounts Receivables
$9.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
18%
|
|
|
Pfizer Inc
NYSE:PFE
|
Accounts Receivables
$11B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accounts Receivables
$11.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accounts Receivables
$7.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
See Also
What is Sonoma Pharmaceuticals Inc's Accounts Receivables?
Accounts Receivables
2.9m
USD
2.9m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Accounts Receivables amounts to 2.9m USD.
What is Sonoma Pharmaceuticals Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
1%
1%
Over the last year, the Accounts Receivables growth was 25%. The average annual Accounts Receivables growth rates for Sonoma Pharmaceuticals Inc have been -13% over the past three years , -2% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet
